Medtech firm Hologic reported better-than-expected Q2 2021 earnings, with EPS of $1.06.

Medtech firm Hologic reported better-than-expected Q2 2021 earnings, with EPS of $1.06 compared to analyst estimates of $1.02. The firm's revenue for the quarter was $1.01 billion, a 2.7% increase year-over-year. Hologic's net margin was 17.59%, and the return on equity was 19.65%. The company has a current ratio of 3.97 and a debt-to-equity ratio of 0.52. Hologic CEO Stephen P. Macmillan sold 3,672 shares of the company's stock for a total value of $294,237.36 on July 17th but still owns 1,157,562 shares in the company. Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health.

August 01, 2024
9 Articles

Further Reading